Strategy to reduce side effects in modern cancer therapy

An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully developed a new strategy for reducing the often serious side effects of an important class of modern anticancer drugs (tyrosine kinase inhibitors). The novel drug is supposed to restrict its activity with high selectivity to the malignant tumour.

The occurrence of severe side effects and the development of resistance are two of the biggest problems facing modern cancer therapy. Even the latest, highly targeted cancer drugs such as the tyrosine kinase inhibitors Tarceva(R) or Sutent(R) are affected by these problems, which can ultimately lead to treatment having to be stopped. The effect of this class of inhibitors is based on the specific inhibition of proteins that are over-activated in cancer cells and which drive abnormal cell growth. However, clinical practice has shown that, as a result of the physiological functions of these proteins in healthy tissue, their inhibition can cause severe side effects. As a result, there is an acute need for strategies to restrict the effect of these highly promising new drugs more selectively to the malignant tumour.

The aim of the research was to develop an improved tyrosine kinase inhibitor that is actually inactive and which is only activated selectively in the malignant tissue. This is intended to prevent damage to healthy tissue and therefore minimise side effects for patients. As part of the paper published in the highly respected journal "Angewandte Chemie [Applied Chemistry], International Edition", a new inhibitor has been successfully synthesised and coordinated to cobalt(III). This leads to initial drug inactivation and, thus, no activity under normal physiological conditions. Only in tumour tissue where, due to the rapid growth, unusually low-oxygen conditions prevail, the inactive cobalt(III) compound is reduced to cobalt(II) and as a result releases the active drug. The tumour-selective effectiveness of this approach has been demonstrated both in living cells and in tumor-bearing organisms.

The development of this complex idea and strategy was made possible by the outstanding interdisciplinary collaboration organised in the context of the "Translational Cancer Therapy Research" platform led by Bernhard Keppler, Dean of the Faculty of Chemistry at the University of Vienna, and Walter Berger, Professor at the Medical University of Vienna. This research platform promotes constant scientific exchange between synthetic chemists at the University of Vienna and cancer researchers at the Medical University of Vienna. It is only through these opportunities that the team of university assistants Christian Kowol (University of Vienna) and Petra Heffeter (Medical University of Vienna) has been able, based on two diploma theses (by Claudia Karnthaler-Benbakka, MSc., and Diana Groza, MSc.), to produce these results. The study was funded by the City of Vienna fund for "innovative interdisciplinary cancer research", the Austrian Science Fund (FWF) and COST CM1105. In view of the highly promising results, the new combination class has been patented by the two universities and currently a partner for further (clinical) development is searched.

So far there has been no comparable strategy for reducing the (severe) side effects of tyrosine kinase inhibitors. As a result, there is hope that, in future, the approach presented here will improve the tolerance of the therapy and allow this treatment to benefit patients who have previously had to discontinue it.

Publication in "Angewandte Chemie, International Edition":
Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation: C. Karnthaler-Benbakka, D. Groza, K. Kryeziu, V. Pichler, A. Roller, W. Berger, P. Heffeter and C. R. Kowol. 2014.
DOI: 10.1002/anie.201403936
http://onlinelibrary.wiley.com/doi/10.1002/anie.201403936/abstract
http://onlinelibrary.wiley.com/doi/10.1002/ange.201403936/abstract


Scientific contacts
O. Univ.-Prof. DDr Bernhard Keppler
Dean of the Faculty of Chemistry
University of Vienna
1090 Vienna, Währinger Strasse 42
T +43-1-4277-526 02
bernhard.keppler(at)univie.ac.at

Dr. Christian Kowol
Institute of Inorganic Chemistry
University of Vienna
1090 Vienna, Währinger Strasse 42
T +43-1-4277-526 09
christian.kowol(at)univie.ac.at

O. Univ.-Prof. Dr Walter Berger
Institute for Cancer Research, Internal Medicine I
Medical University of Vienna
1090 Vienna, Borschkegasse 8A
T +43-1-40160-57555
walter.berger(at)meduniwien.ac.at

Dr. Petra Heffeter, MAS
Institute for Cancer Research, Internal Medicine I
Medical University of Vienna
1090 Vienna, Borschkegasse 8A
T +43-1-40160-57557
petra.heffeter(at)meduniwien.ac.at

Press contacts
Mag. Veronika Schallhart
University of Vienna Press Office
Research and Teaching
1010 Vienna, Universitätsring 1
T +43-1-4277-175 30
M +43-664-602 77-175 30
veronika.schallhart(at)univie.ac.at

Mag. Johannes Angerer
Communication and Public Relations
Medical University of Vienna
1090 Vienna, Spitalgasse 23
T +43-1-40160-11501
M +43-664-800-16 11 501
johannes.angerer(at)meduniwien.ac.at

Wissenschaftlicher Kontakt

Dr. Christian Kowol

Institut für Anorganische Chemie
Universität Wien
1090 - Wien, Währinger Straße 42
+43-1-4277-526 09
christian.kowol@univie.ac.at

Rückfragehinweis

Mag. Veronika Schallhart

Pressebüro der Universität Wien
Forschung und Lehre
1010 - Wien, Universitätsring 1
+43-1-4277-175 30
+43-664-602 77-175 30
veronika.schallhart@univie.ac.at